Table 2.
Baseline characteristics of patients according to the development of HCC after DAA therapy
| Characteristics | Patients without HCC after DAA | Patients with HCC after DAA | P‐value |
|---|---|---|---|
| Age (years) | 70.8 (16–88) | 77.0 (65–85) | <0.001 |
| Sex (female/male) | 129 (52.9%)/115 (47.1%) | 12 (63.2%)/7 (36.8%) | 0.477 |
| HCV genotype (1b/2a or 2b) | 181/63 | 17/2 | 0.173 |
| HCC history (absent/present) | 226/18 | 7/12 | <0.001 |
| Body mass index (kg/m2) | 22.5 (15.0–32.9) | 23.3 (16.4–31.5) | 0.563 |
| Serum albumin (g/dL) | 4.0 (2.2–4.9) | 3.8 (2.4–4.5) | 0.097 |
| Total bilirubin (mg/dL) | 0.72 (0.3–2.5) | 0.98 (0.6–2.6) | 0.001 |
| Alanine aminotransferase (IU/L) | 34.5 (10–299) | 24.5 (14–106) | 0.321 |
| Aspartate aminotransferase (IU/L) | 38.4 (16–224) | 43.0 (27–106) | 0.155 |
| Gamma‐glutamyl transpeptidase (IU/L) | 31.7 (8–521) | 21.5 (13–521) | 0.519 |
| Platelet count (×103/μL) | 151 (14–351) | 118 (38–221) | 0.005 |
| α‐Fetoprotein (ng/mL) | 4.4 (0.9–172.3) | 6.3 (2.5–132.5) | 0.011 |
| Liver stiffness (m/s) | 1.39 (0.67–4.35) | 2.04 (1.12–4.00) | <0.001 |
DAA, direct‐acting antiviral; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.